ALUTARD SQ Felis domesticus

Small molecule

UUniversity of Zurich

ALUTARD SQ Felis domesticus is one of 33 small molecule programs targeting Allergy. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AllergyActive, not recruiting

AllergyPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

149 competitors in Allergy

#DrugCompanyPhaseTrials

Flovent

GSK

Phase 3

1 2

Clarinex

OOrganon and Co

Phase 3

1 3

Xolair

Roche

Phase 2

7 4

REGN5715

Regeneron

Phase 3

1 5

REGN5713

Regeneron

Phase 3

1 6

Rhapsido

Novartis

Phase 2

1 7

Ligelizumab

Novartis

Phase 3

1 8

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Phase 2

3 9

Elspar

DDutch Childhood Oncology Group

Phase 2

1 10

Adrenaline

SSamson Clinical Operations Pty Ltd

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 1/2Recruiting

Allergy

NCT06960382

Clinical

Trials by Indication[1]

Allergy1 trial

Safety and Immunogenicity of Cat-allergen Intralymphatic Immunotherapy in Patients With Cat Allergy With and Without Asthma

Recruiting·UUniversity of Zurich·Phase 1/2·NCT06960382·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for ALUTARD SQ Felis domesticus. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALUTARD SQ Felis domesticus compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALUTARD SQ Felis domesticus. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Zurich company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: UUniversity of Zurich

ALUTARD SQ Felis domesticus

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Allergy1 trial

References

Drug Info

Quick Facts

Related News